Biomind Labs Inc.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more
Biomind Labs Inc. (BMNDF) - Net Assets
Latest net assets as of September 2025: $-1.56 Million USD
Based on the latest financial reports, Biomind Labs Inc. (BMNDF) has net assets worth $-1.56 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($57.66K) and total liabilities ($1.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.56 Million |
| % of Total Assets | -2703.01% |
| Annual Growth Rate | N/A |
| 5-Year Change | -5127.81% |
| 10-Year Change | N/A |
| Growth Volatility | 2954.41 |
Biomind Labs Inc. - Net Assets Trend (2015–2024)
This chart illustrates how Biomind Labs Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biomind Labs Inc. (2015–2024)
The table below shows the annual net assets of Biomind Labs Inc. from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.30 Million | +9.21% |
| 2023-12-31 | $-1.43 Million | -478.27% |
| 2022-12-31 | $-247.66K | -111.29% |
| 2021-12-31 | $2.19 Million | +8380.32% |
| 2020-12-31 | $25.86K | -91.88% |
| 2019-12-31 | $318.52K | -75.74% |
| 2018-12-31 | $1.31 Million | -92.33% |
| 2017-12-31 | $17.11 Million | +0.59% |
| 2016-12-31 | $17.01 Million | +0.12% |
| 2015-12-31 | $16.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biomind Labs Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 889434000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.45 Million | % |
| Other Comprehensive Income | $2.14 Million | % |
| Total Equity | $-1.30 Million | 100.00% |
Biomind Labs Inc. Competitors by Market Cap
The table below lists competitors of Biomind Labs Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Integrum AB Series B
ST:INTEG-B
|
$10.18 Million |
|
RP Optical Lab Ltd
TA:RPOL
|
$10.18 Million |
|
Profoto Holding AB
ST:PRFO
|
$10.19 Million |
|
Advance Metals Ltd
AU:AVM
|
$10.19 Million |
|
ReVolve Renewable Power Corp.
OTCQB:REVVF
|
$10.18 Million |
|
Burgundy Diamond Mines Ltd
AU:BDM
|
$10.17 Million |
|
Iris Business Services Limited
NSE:IRIS
|
$10.17 Million |
|
Netcare
JSE:NTC
|
$10.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biomind Labs Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,424,792 to -1,300,192, a change of 124,600.
- Net loss of 260,479 reduced equity.
- Other comprehensive income increased equity by 58,692.
- Other factors increased equity by 326,387.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-260.48K | -20.03% |
| Other Comprehensive Income | $58.69K | +4.51% |
| Other Changes | $326.39K | +25.1% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Biomind Labs Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.10 | $0.70 | x |
| 2016-12-31 | $0.10 | $0.70 | x |
| 2017-12-31 | $0.09 | $0.70 | x |
| 2018-12-31 | $0.14 | $0.70 | x |
| 2019-12-31 | $0.03 | $0.70 | x |
| 2020-12-31 | $0.00 | $0.70 | x |
| 2021-12-31 | $0.03 | $0.70 | x |
| 2022-12-31 | $0.00 | $0.70 | x |
| 2023-12-31 | $-0.02 | $0.70 | x |
| 2024-12-31 | $-0.02 | $0.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biomind Labs Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-117.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -9.09% | -320.50% | 0.02x | 1.14x | $-2.88 Million |
| 2016 | -4.08% | -189.78% | 0.02x | 1.14x | $-2.12 Million |
| 2017 | -24.13% | -390.64% | 0.06x | 1.12x | $-5.30 Million |
| 2018 | -86.45% | -281.12% | 0.26x | 1.20x | $-1.27 Million |
| 2019 | -114.28% | -1739.38% | 0.06x | 1.16x | $-395.85K |
| 2020 | -734.73% | -7341.58% | 0.03x | 3.39x | $-192.59K |
| 2021 | -197.54% | 0.00% | 0.00x | 1.15x | $-4.55 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.96 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.07 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-130.46K |
Industry Comparison
This section compares Biomind Labs Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biomind Labs Inc. (BMNDF) | $-1.56 Million | -9.09% | N/A | $10.18 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |